Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial

Combining standard of care (pertuzumab-trastuzumab [PH], chemotherapy) with cancer immunotherapy may potentiate antitumor immunity, cytotoxic activity, and patient outcomes in high-risk, human epidermal growth factor receptor 2 (HER2)–positive early breast cancer. We report the phase III IMpassion05...

Descripción completa

Detalles Bibliográficos
Autores principales: Huober, Jens, Barrios, Carlos H., Niikura, Naoki, Jarząb, Michał, Chang, Yuan-Ching, Huggins-Puhalla, Shannon L., Pedrini, José, Zhukova, Lyudmila, Graupner, Vilma, Eiger, Daniel, Henschel, Volkmar, Gochitashvili, Nino, Lambertini, Chiara, Restuccia, Eleonora, Zhang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426828/
https://www.ncbi.nlm.nih.gov/pubmed/35763704
http://dx.doi.org/10.1200/JCO.21.02772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426828/
https://www.ncbi.nlm.nih.gov/pubmed/35763704
http://dx.doi.org/10.1200/JCO.21.02772

Ejemplares similares